XML 62 R32.htm IDEA: XBRL DOCUMENT
v3.25.1

NET FINANCIAL RESULT | 12 Months Ended
--- | ---
Dec. 31, 2024
NET FINANCIAL RESULT |
NET FINANCIAL RESULT | 26 NET FINANCIAL RESULT
|  | 12/31/2024 |  | 12/31/2023 |  | 12/31/2022
Financial expenses |  |  |  |  |  |
Interest on loans, financing and debentures (1) |  | (4,453,739) |  |  | (3,636,730) |  |  | (3,648,330) |
Amortization of transaction costs (2) |  | (80,099) |  |  | (67,353) |  |  | (69,881) |
Interest expenses on lease liabilities (3) |  | (451,148) |  |  | (441,596) |  |  | (433,613) |
Amortization of fair value adjustment |  |  |  |  |  |  | (18,887) |
Other |  | (556,917) |  |  | (513,483) |  |  | (419,659) |
|  | (5,541,903) |  |  | (4,659,162) |  |  | (4,590,370) |
Financial income |  |  |  |  |  |
Cash and cash equivalents and marketable securities |  | 1,598,111 |  |  | 1,668,408 |  |  | 818,780 |
Other |  | 139,323 |  |  | 157,241 |  |  | 148,230 |
|  | 1,737,434 |  |  | 1,825,649 |  |  | 967,010 |
Results from derivative financial instruments |  |  |  |  |  |
Income |  | 2,669,394 |  |  | 10,149,730 |  |  | 11,969,288 |
Expenses |  | (11,782,077) |  |  | (4,623,016) |  |  | (5,207,721) |
|  | (9,112,683) |  |  | 5,526,714 |  |  | 6,761,567 |
Monetary and exchange rate variations, net |  |  |  |  |  |
Exchange rate variations on loans, financing and debentures |  | (17,728,324) |  |  | 4,185,675 |  |  | 3,949,020 |
Leases |  | (613,124) |  |  | 180,112 |  |  | 186,241 |
Other assets and liabilities (4) |  | 2,456,455 |  |  | (1,278,060) |  |  | (840,668) |
|  | (15,884,993) |  |  | 3,087,727 |  |  | 3,294,593 |
Net financial result |  | (28,802,145) |  |  | 5,780,928 |  | 6,432,800
(1)Excludes R$959,968 arising from capitalized loan costs, substantially related to property, plant and equipment in progress of the Cerrado Project for the year ended December 31, 2024 (R$1,160,364 as at December 31, 2023). (2)On December 31, 2023, in the consolidated statements, the balance of R$19 relating to transaction costs with loans and financing was recognized directly in the income statement. (3)Includes R$249,135 referring to the reclassification to the biological assets item for the composition of the formation cost (R$223,055 as of December 31, 2023). (4)Includes effects of exchange rate variations of trade accounts receivable, trade accounts payable, cash and cash equivalents, marketable securities and others.

X
- References No definition available. + Details
Name: | suz_DisclosureOfFinancialResultsAbstract
Namespace Prefix: | suz_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of finance income (cost). + References No definition available. + Details
Name: | suz_DisclosureOfFinancialResultsTextBlock
Namespace Prefix: | suz_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration